Daily briefing · Sep 19, 2026

Brain regions trace to two embryonic origins

A Nature Neuroscience study traced two separate embryonic progenitor populations in mice: one forms the forebrain and midbrain, the other the hindbrain. The team also generated functional human hindbrain motor neurons from pluripotent stem cells and found related lineage patterns across distant animal groups. The work revises a basic model of brain development and may improve laboratory research on disorders affecting hindbrain neurons, including ALS and spinal muscular atrophy; it does not itself provide a treatment. Two parallel neural ectoderm progenitors contribute to the developing brain · Human brain is two separate organs, Stanford Medicine-led research finds

FDA approves targeted breast-cancer combination

The FDA approved imlunestrant with abemaciclib for adults with previously treated, ER-positive, HER2-negative advanced or metastatic breast cancer carrying an ESR1 mutation. In an exploratory subgroup of 159 trial participants, median progression-free survival was 11.1 months with the combination versus 5.5 months with imlunestrant alone; overall-survival data remain immature. The approval adds an oral, biomarker-selected option after endocrine therapy stops working, but its reported benefit applies to the specified mutation-defined population and the medicines carry potentially serious risks. FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

Malaysia seeks company plans for possible El Niño

Malaysia’s Securities Commission intends to ask major listed companies how they are preparing for a possible strong El Niño, its chairman told Reuters. The regulator plans to follow up next year by comparing climate-risk disclosures with companies’ actual preparations, particularly for drought and water stress. Hotter, drier conditions could affect water supplies, crop yields and Malaysia’s economically important palm-oil industry. The exercise may also show whether corporate climate disclosures translate into practical measures rather than descriptions of general risk. Malaysian regulator to ask publicly-traded firms for El Nino plans, eyes deeper Middle East ties

Every US state applies to Medicaid drug-price model

All 50 states, the District of Columbia and Puerto Rico applied to the voluntary GENEROUS Medicaid model, which uses supplemental manufacturer rebates to align prices for participating medicines with prices in certain other countries. CMS said 40 states and Puerto Rico had signed agreements, while the remaining states had until September 30. The five-year model began in January 2026, and CMS projects $64.3 billion in government savings over ten years. That figure remains an agency estimate rather than a measured result. CMS Announces Participants in Landmark Medicaid Drug Payment Model to Bring Down Drug Costs for Most Vulnerable Americans